Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines

US8394385B2 · kind B2 · utility

Assignee

• Bavarian Nordic A/S · DK

Inventors

• Jürgen Hausmann · Gundelfingen, DE
• Karen Baur · Munich, DE
• Kay Brinkmann · Munich, DE

Key dates

• Filing date: Mar 9, 2010
• Grant date: Mar 12, 2013
• Expiry date: Apr 9, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2830/60
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is drawn to compositions and methods for the induction of a strong CD8 T cell response to a specific antigen(s). The combination of an early/late hybrid promoter directing strongly enhanced early expression of a neoantigen with at least three immunization rounds resulted in a highly efficient neoantigen-specific CD8 T cell response. This combination reversed the immunodominance hierarchy and converted a moderately immunogenic and subdominant CD8 T cell epitope into the immunodominant epitope.